A phase IIIb, open label, randomized, exploratory clinical study exploring efficacy, safety and patients satisfaction with Certolizumab pegol treatment in moderate to severe Crohn's disease when treatment is administered in two different settings : either at hospital or at home.

Trial Profile

A phase IIIb, open label, randomized, exploratory clinical study exploring efficacy, safety and patients satisfaction with Certolizumab pegol treatment in moderate to severe Crohn's disease when treatment is administered in two different settings : either at hospital or at home.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2012

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms PERFECT
  • Sponsors UCB Pharma SA
  • Most Recent Events

    • 27 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top